We investigated the potential effects of Costaria costata (CC) on atopic dermatitis (AD) development in chloro-2,4-dinitrobenzene (DNCB)-treated NC/Nga mice. CC is a brown alga distributed across the seas of Korea, China, and Japan. A total of 40 mice were randomly assigned to 5 groups with 8 mice per group: untreated Balb/c mice, AD control (0.1% w/v DNCB-treated NC/Nga mice), positive control (i.e., DNCB-treated NC/Nga mice fed a dietary supplement of 66.6 mg/kg of body weight [b.w.] of CJLP133), DNCB-treated NC/Nga mice fed a dietary supplement of 100 mg/kg b.w. of CCE10 (CCE10 100), and DNCB-treated mice fed a dietary supplement of 300 mg/kg b.w. of CCE10 (CCE10 300) groups. The CCE10 100 and CCE10 300 treatment groups suppressed AD development including clinical and histopathological changes and a reduction in skin hydration induced by DNCB. In addition, Th2 cytokine production in primary splenocytes, serum IgE and histamine production, and mast cell infiltration into the skin were suppressed in the CCE10 300 mice compared to the CCE10 100 mice. Our finding demonstrated an inhibitory effect of CCE10 in AD development by means of improving the Th1/Th2 cytokine balance and anti-inflammatory effect in an in vivo model.

1.
Gittler JK, Krueger JG, Guttman-Yassky E: Atopic dermatitis results in intrinsic barrier and immune abnormalities: implications for contact dermatitis. J Allergy Clin Immunol 2013; 131: 300–313.
2.
Bieber T: Atopic dermatitis: N Engl J Med 2008; 358: 1483–1494.
3.
Novak N, Peng W, Yu C: Network of myeloid and plasmacytoid dendritic cells in atopic dermatitis. Adv Exp Med Biol 2007; 601: 97–104.
4.
Sullivan M, Silverberg NB: Current and emerging concepts in atopic dermatitis pathogenesis. Clin Dermatol 2017; 35: 349–353.
5.
Malik K, Heitmiller KD, Czarnowicki T: An update on the pathophysiology of atopic dermatitis. Dermatol Clin 2017; 35: 317–326.
6.
Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, Hoetzenecker W, Knol E, Simon HU, Wollenberg A, Bieber T, Lauener R, Schmid-Grendelmeier P, Traidl-Hoffmann C, Akdis CA: Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol 2016; 138: 336–349.
7.
Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al: Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006; 38: 441–446.
8.
Albanesi C, Pastore S: Pathobiology of chronic inflammatory skin diseases: interplay between keratinocytes and immune cells as a target for anti-inflammatory drugs. Curr Drug Metab 2010; 11: 210–227.
9.
Amerio P, Frezzolini A, Feliciani C, Verdolini R, Teofoli P, De Pità O, Puddu P: Eotaxins and CCR3 receptor in inflammatory and allergic skin diseases: therapeutical implications. Curr Drug Targets Inflamm Allergy 2003; 2: 81–94.
10.
Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N: Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis. Pediatr Allergy Immunol 2008; 19: 605–613.
11.
Böhm I, Bauer R: Th1 cells, Th2 cells and atopic dermatitis. Hautarzt 1997; 48: 223–227.
12.
Homey B, Steinhoff M, Ruzicka T, Leung DY: Cytokines and chemokines orchestrate atopic skin inflammation. J Allergy Clin Immunol 2006; 118: 178–189.
13.
Kashiwada M, Levy DM, McKeag L, Murray K, Schröder AJ, Canfield SM, Traver G, Rothman PB: IL-4-induced transcription factor NFIL3/E4BP4 controls IgE class switching. Proc Natl Acad Sci 2010; 107: 821–826.
14.
Simon D, Bieber T: Systemic therapy for atopic dermatitis. Allergy 2014; 69: 46–55.
15.
Hughes R, Ward D, Tobin AM, Keegan K, Kirby B: The use of alternative medicine in pediatric patients with atopic dermatitis. Pediatr Dermatol 2007; 24: 118–120.
16.
Anastyuk SD, Imbs TI, Shevchenko NM, Dmitrenok PS, Zvyagintseva TN: ESIMS analysis of fucoidan preparations from Costaria costata, extracted from alga at different life-stages. Carbohydr Polym 2012; 90: 993–1002.
17.
Maruyama H, Tamauchi H, Kawakami F, Yoshinaga K, Nakano T: Suppressive effect of dietary fucoidan on proinflammatory immune response and MMP-1 expression in UVB-irradiated mouse skin. Planta Med 2015; 81: 1370–1374.
18.
Jeong SC, Jeong YT, Lee SM, Kim JH: Immune-modulating activities of polysaccharides extracted from brown algae Hizikia fusiforme. Biosci Biotechnol Biochem 2015; 79: 1362–1365.
19.
Wang Q, Song Y, He Y, Ren D, Kow F, Qiao Z, Liu S, Yu X: Structural characterisation of algae Costaria costata fucoidan and its effects on CCL4-induced liver injury. Carbohydr Polym 2014; 107: 247–254.
20.
Ermakova S, Sokolova R, Kim SM, Um BH, Isakov V, Zvyagintseva T: Fucoidans from brown seaweeds Sargassum hornery, Eclonia cava, Costaria costata: structural characteristics and anticancer activity. Appl Biochem Biotechnol 2011; 164: 841–850.
21.
Kim OK, Nam DE, Lee M, Kwon HO, Park J, You Y, Kim SI, Lee J, Jun W: The effects of Costaria costata extracts on atopic dermatitis in an in vitro model. J Med Food 2016; 19: 1–7.
22.
Han Y, Kim B, Ban J, Lee J, Kim BJ, Choi BS, Hwang S, Ahn K, Kim J: A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol 2012; 23: 667–673.
23.
Gao XK, Nakamura N, Fuseda K, Tanaka H, Inagaki N, Nagai H: Establishment of allergic dermatitis in NC/Nga mice as a model for severe atopic dermatitis. Biol Pharm Bull 2004; 27: 1376–1381.
24.
Heo JY, Cho YS, Cheon HG: Topical effects of roflumilast on 1-chloro-2,4-dinitrobenzene-induced atopic dermatitis-like skin lesions in NC/Nga mice. Pharmazie 2010; 65: 906–912.
25.
Shoda T, Futamura K, Kobayashi F, Saito H, Matsumoto K, Matsuda A: Expression of thymus and activation-regulated chemokine (TARC) by human dermal cells, but not epidermal keratinocytes. J Dermatol Sci 2014; 76: 90–95.
26.
Matsuda H, Watanabe N, Geba GP, Sperl J, Tsudzuki M, Hiroi J, Matsumoto M, Ushio H, Saito S, Askenase PW, Ra C: Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 1997; 9: 461–466.
27.
Eberlein-König B, Schäfer T, Huss-Marp J, Darsow U, Möhrenschlager M, Herbert O, Abeck D, Krämer U, Behrendt H, Ring J: Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children. Acta Derm Venereol 2000; 80: 188–191.
28.
Grewe M, Bruijnzeel-Koomen CA, Schöpf E, Thepen T, Langeveld-Wildschut AG, Ruzicka T, Krutmann J: A role for Th1 and Th2 cells in the immunopathogenesis of atopic dermatitis. Immunol Today 1998; 19: 359–361.
29.
Wershil BK, Murakami T, Galli SJ: Mast cell-dependent amplification of an immunologically nonspecific inflammatory response. Mast cells are required for the full expression of cutaneous acute inflammation induced by phorbol 12-myristate 13-acetate. J Immunol 1988; 140: 2356–2360.
30.
Blank U, Rivera J: The ins and outs of IgE-dependent mast-cell exocytosis. Trends Immunol 2004; 25: 266–273.
31.
Glatzer F, Gschwandtner M, Ehling S, Rossbach K, Janik K, Klos A, Bäumer W, Kietzmann M, Werfel T, Gutzmer R: Histamine induces proliferation in keratinocytes from patients with atopic dermatitis through the histamine 4 receptor. J Allergy Clin Immunol 2013 ; 132: 1358–1367.
32.
Chung BY, Cho SI, Ahn IS, Lee HB, Kim HO, Park CW, Lee CH: Treatment of atopic dermatitis with a low-histamine diet. Ann Dermatol 2011; 23:S91–S95.
33.
Kang BK, Kim MJ, Kim KB, Ahn DH: In vivo and in vitro inhibitory activity of an ethanolic extract of Sargassum fulvellum and its component grasshopper ketone on atopic dermatitis. Int Immunopharmacol 2016; 40: 176–183.
34.
Choi JS, Moon WS, Choi JN, Do KH, Moon SH, Cho KK, Han CJ, Choi IS: Effects of seaweed Laminaria japonica extracts on skin moisturizing activity in vivo. J Cosmet Sci 2013; 64: 193–205.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.